AlphaCrest Capital Management’s Corcept Therapeutics CORT Stock Holding History

AlphaCrest Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-49,810	Closed	-$1.28M	–	257
2022 Q3	$1.28M	Sell	49,810 -10,608	-18%	-$284K	0.08%	453
2022 Q2	$1.44M	Sell	60,418 -57,645	-49%	-$1.26M	0.07%	494
2022 Q1	$2.66M	Sell	118,063 -11,794	-9%	-$251K	0.15%	153
2021 Q4	$2.57M	Buy	129,857 +28,562	+28%	+$579K	0.1%	301
2021 Q3	$1.99M	Buy	101,295 +64,048	+172%	+$1.34M	0.1%	303
2021 Q2	$819K	Sell	37,247 -35,248	-49%	-$784K	0.04%	755
2021 Q1	$1.73M	Buy	+72,495	New	+$1.94M	0.1%	310
2020 Q3	–	Sell	-37,295	Closed	-$627K	–	1102
2020 Q2	$627K	Buy	+37,295	New	+$524K	0.1%	298
2020 Q1	–	Sell	-30,600	Closed	-$370K	–	1056
2019 Q4	$370K	Sell	30,600 -56,500	-65%	-$787K	0.03%	955
2019 Q3	$1.23M	Buy	87,100 +58,100	+200%	+$714K	0.07%	458
2019 Q2	$323K	Sell	29,000 -41,400	-59%	-$461K	0.03%	841
2019 Q1	$826K	Buy	70,400 +50,900	+261%	+$633K	0.13%	259
2018 Q4	$261K	Buy	+19,500	New	+$258K	0.08%	508

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's CORT Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 49,810 shares — an estimated $1.28M sold.

AlphaCrest Capital Management first reported a position in CORT in Q4 2018 and held it in 13 quarters. The position peaked at $2.66M in Q1 2022. 243 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

AlphaCrest Capital Management reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 49,810 Corcept Therapeutics shares in Q4 2022, an estimated $1.28M.
AlphaCrest Capital Management first reported a position in Corcept Therapeutics in Q4 2018 and held it in 13 quarters.
AlphaCrest Capital Management's Corcept Therapeutics position peaked at $2.66M in Q1 2022.
243 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.